Bryophyllum Anxiety Treatment Study: Patient Outcomes and Predictors

54 patients with anxiety symptoms were treated with Bryophyllum 50% chewable tablets for two weeks in a prospective, single-arm study. The dataset, published by figshare admin karger, contains supplementary material analyzing variables associated with changes in Beck Anxiety Inventory (BAI) scores. It was last updated on 2026-04-28.

Use Cases

• Identifying patient subgroups with greater treatment response based on age and baseline anxiety severity mentioned in the description.
• Analyzing the association between benzodiazepine use and anxiety symptom reduction as described in the results.
• Exploring the relationship between depression scores (PHQ-9) and anxiety outcomes as referenced in the multivariate analysis.

Strengths

• Includes data from 54 patients with detailed pre- and post-treatment Beck Anxiety Inventory scores.
• Multivariate analysis results are described, indicating associations with age and baseline anxiety severity.
• Dataset is openly licensed under CC-BY-4.0 for reuse.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The study design is a single-arm trial without a control group, limiting causal inference as noted in the conclusion.

Provenance

Source

figshare admin karger

Collection Method

Secondary analysis of a prospective, single-arm clinical study conducted at Klinik Arlesheim, Department of Psychiatry and Psychosomatics.

Freshness

Last updated 2026-04-28 05:55:14; freshness should be verified.

Geography

Likely Switzerland (study conducted at Klinik Arlesheim, Arlesheim).